Article
Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences - 1 Aug 2022
Yuan Wei, Zhang Shizhong, Zhu Honghu
Abstract excerpt
Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy. AML patients with FLT3 mutations tend to have a high relapse rate and poor outcome, so FLT3 gene has become an important target for AML treatment, and a series of FLT3 inhibitors have been developed. According to the characteristics of FLT3 inhibitors, they can be divided into first-generation FLT3 inhibitors and second-generation...
Topics
- Humans
- Protein Kinase Inhibitors
- Mutation
- Prognosis
- Recurrence
- Leukemia, Myeloid, Acute
- Antineoplastic Agents
- Tumor Microenvironment
- fms-Like Tyrosine Kinase 3